Latest news

• Merck gets first approval for MET inhibitor tepotinib in Japan

  First worldwide approval for MET inhibitor. Japan’s medicines regulator has approved Merck KGaA’s oral MET inhibitor tepotinib for non-small cell lung cancer with MET exon 14 (METex14) mutations, ... The Japanese approval is the first worldwide for

• Incyte’s JAK inhibitor cream clears second eczema trial

  The reformulation could open up a new and very large treatment category for the drug, as well as new territory for the JAK inhibitor class. ... The oral JAK inhibitor market is split between drugs used to treat cancer, like Jakafi, and those used for

• Novartis pulls ahead of Merck in MET-positive lung cancer race

  FDA starts priority review of Swiss pharma's MET inhibitor. Novartis’ MET inhibitor capmatinib could be approved for marketing in the US within six months for a rare form of ... The start of the review puts Novartis in a position to bring a drug for MET

• Exelixis bounces back with new prostate cancer data

  It seems like that sacrifice was worth it, with cabozantinib in combination with PD-1 inhibitor Tecentriq (atezolizumab) hitting the primary endpoint of an improved objective response rate. ... Cabozantinib, a c-MET and VEGFR2 inhibitor, is already

• Merck buys ArQule for $2.7bn in another cancer bolt-on deal

  The deal – due to close in the first quarter of 2020 – will give Merck ownership of ARQ 531, a BTK inhibitor that has just reported more encouraging data in B-cell ... trials, with recent fails including c-MET inhibitor tivantinib.